Objective To understand the role of the genetic changes and bone marrow
microenvironment on the development, progression, and staging of multiple myeloma (MM) …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal
gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic …

Simple Summary A clinical decision and study design investigating the level and extent of
angiogenesis modulation aimed at vascular normalization without rendering tissues hypoxic …

Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the
bone marrow (BM). It represents the final stage in a continuum of PC dyscrasias and is …

Despite significant advances in the treatment of multiple myeloma (MM), most patients
succumb to disease progression. One of the major immunosuppressive mechanisms that is …

Interactions of malignant multiple myeloma (MM) plasma cells with the microenvironment
control MM plasma-cell growth, survival, drug-resistance and dissemination. As …

Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and involves
direct production of angiogenic cytokines by plasma cells and their induction within the bone …

Multiple myeloma (MM) is a genetically heterogeneous disease that includes a subgroup of
10–15% of patients facing dismal survival despite the most intensive treatment. Despite …

In the year 2000, Hanahan and Weinberg defined the six Hallmarks of Cancer as: self-
sufficiency in growth signals, evasion of apoptosis, insensitivity to antigrowth mechanisms …